What do we know when a new medicine is approved? What are the regulatory requirements for new medicines? What happens once a new drug is on the market?Following the first of the EPHA #A2MDialogues, our panelists Andrea Cipriani, Lydie Meheus, Huseyin Naci and Beate...
Throughout the reform of the EU Common Agricultural Policy (CAP), many opportunities for the CAP to genuinely support public health objectives, such as healthy food environments, planetary health objectives, fair working conditions and the phase out of health-harming...
The first thousand days of a child’s life are vital for their optimal physical and mental development and the realization of their full potential. The lack of adequate nutrition, quality healthcare and prevention services, vaccination, affordable medicines, learning...
DOWNLOAD THE PAPER DOWNLOAD THE PR The increasing levels of medicine shortages across Europe pose severe threats to patient outcomes, patient safety and the patient care continuum. The European Public Health Alliance (EPHA) calls for an urgent resolution of the...
Download the analysis The intergovernmental regional initiatives of collaboration around access to medicines policy are here to stay. Zooming in on the BeNeLuxA coalition, the most advanced of the regional European clusters (henceforth the regionals), this reflection...
DOWNLOAD THE PAPER A new EPHA Reflection Paper explores the potential of Artificial Intelligence (AI) – and the Big Data on which it relies – in the context of the evolving digital transformation of health and care at the EU level. The paper proposes to look beyond...